10.3 Infectious Complications in People Who Inject Drugs: Viral Hepatitis, HIV, Endocarditis & PrEP/PEP
Key Takeaways
- DAA pangenotypic regimens (glecaprevir/pibrentasvir for 8 weeks or sofosbuvir/velpatasvir for 12 weeks) cure chronic HCV in >95-98%; guidelines forbid requiring sobriety before treatment.
- Hepatitis B vaccination is recommended for all PWID; accelerated 2-dose adjuvanted series (Heplisav-B at 0 and 1 month) significantly enhances series completion compared to 6-month schedules.
- For HIV PrEP in PWID, oral TDF/FTC (Truvada) and injectable cabotegravir (Apretude) are FDA-approved, whereas TAF/FTC (Descovy) is NOT approved for injection-related exposure.
- Post-Exposure Prophylaxis (PEP) must be initiated within 72 hours of unsterile needle or sexual exposure and continued as a 28-day three-drug antiretroviral regimen.
- Tricuspid valve infective endocarditis (most commonly S. aureus) presents with septic pulmonary emboli; providing MOUD and addiction consultation prevents AMA discharges, enabling completion of 4-6 weeks of parenteral antibiotics.
Infectious Complications in People Who Inject Drugs: Viral Hepatitis, HIV, Endocarditis & PrEP/PEP
People Who Inject Drugs (PWID) experience disproportionate morbidity and mortality from severe infectious complications. Infectious risks stem from complex bio-behavioral dynamics: direct vascular inoculation of skin flora, contaminated diluents, sharing of syringes and drug preparation paraphernalia (cookers, filters, rinse water), structural poverty, and clinical stigmatization that delays healthcare engagement. For the Certified Addictions Registered Nurse - Advanced Practice (CARN-AP), clinical competency requires mastering the diagnostic nuances of viral hepatitis and retroviruses, prescribing modern curative and prophylactic regimens, and managing severe, life-threatening invasive bacterial and fungal infections within a compassionate, harm-reduction framework.
Hepatitis C Virus (HCV): Universal Screening, Reflex RNA & Direct-Acting Antivirals (DAAs)
Hepatitis C Virus (HCV) is an enveloped, positive-sense single-stranded RNA flavivirus that represents the most prevalent bloodborne viral infection among PWID in North America. Injection drug use accounts for over 70% to 80% of all incident HCV infections.
HCV DIAGNOSTIC SCREENING ALGORITHM
HCV Antibody Test with Reflex
|
+------------------------+------------------------+
| |
HCV Antibody Non-Reactive HCV Antibody Reactive
| |
No active HCV infection REFLEX TESTING: HCV RNA PCR
(Retest if recent exposure <6 mo) |
+------------------------+------------------------+
| |
HCV RNA Undetectable HCV RNA Detectable
| |
Prior Resolved Infection OR ACTIVE CHRONIC HCV INFECTION
Spontaneous Clearance (~15-25%) Evaluate for Immediate DAA Therapy
Screening and Diagnostic Guidelines
- Universal Screening: The U.S. Preventive Services Task Force (USPSTF) and the Centers for Disease Control and Prevention (CDC) recommend universal one-time HCV screening for all adults aged 18 and older, and universal screening for all pregnant persons during each pregnancy.
- Targeted Routine Screening for PWID: Routine periodic screening (at least annually, and every 3 to 6 months for individuals with persistent high-risk injection practices) is mandatory for all PWID.
- Reflex Testing Standard: Clinicians must order HCV Antibody with Reflex to HCV RNA PCR. An isolated positive HCV antibody indicates exposure at some point in life but cannot differentiate between active viremia, spontaneous clearance (which occurs in 15% to 25% of individuals), or previously cured infection. If the antibody is reactive, reflex HCV RNA quantification confirms active viremia.
Pangenotypic Direct-Acting Antiviral (DAA) Regimens
The advent of oral Direct-Acting Antivirals (DAAs) transformed HCV from a chronic, morbid illness into a curable infection, achieving Sustained Virologic Response at 12 weeks post-treatment (SVR12) rates exceeding 95% to 98%.
+---------------------------------------------------------------------------------------------------------+
| FIRST-LINE PANGENOTYPIC DAA REGIMENS (NON-CIRRHOTIC NAIVE) |
+----------------------------+-------------------------------------+--------------------------------------+
| Pharmacological Regimen | Dosing Schedule | Duration & Clinical Considerations |
+----------------------------+-------------------------------------+--------------------------------------+
| Glecaprevir / Pibrentasvir | 3 co-formulated tablets (100 mg / | 8 WEEKS total duration |
| (Mavyret) | 40 mg each) PO ONCE daily WITH FOOD | Short course; excellent for PWID; |
| | (NS3/4A protease + NS5A inhibitor) | protease inhibitor (caution in liver)|
+----------------------------+-------------------------------------+--------------------------------------+
| Sofosbuvir / Velpatasvir | 1 co-formulated tablet (400 mg / | 12 WEEKS total duration |
| (Epclusa) | 100 mg) PO ONCE daily with or | Single daily pill; minimal drug |
| | without food (NS5B + NS5A inhibitor)| interactions; safe across all stages |
+----------------------------+-------------------------------------+--------------------------------------+
Overcoming Barriers: The Sobriety Mandate Fallacy
Historically, third-party payers, healthcare systems, and clinicians enforced discriminatory policies requiring 3 to 6 months of verified chemical abstinence or negative urine drug screens prior to initiating DAA therapy. Clinical trials and real-world implementation studies (e.g., the SIMPLIFY and HERO studies) have thoroughly debunked this rationale:
- Equal SVR12 Rates: PWID who are actively using drugs achieve SVR12 cure rates (>94% to 98%) comparable to non-drug-using populations.
- Guideline Mandate: Current AASLD/IDSA (American Association for the Study of Liver Diseases / Infectious Diseases Society of America) and ASAM clinical guidelines unequivocally mandate that active injection drug use is NOT a contraindication to HCV therapy. Sobriety requirements are medically unjustified, stigmatizing, and violate modern standards of care.
- Treatment as Prevention (TasP): Curing HCV in active PWID directly clears the community viral reservoir, preventing secondary transmissions across injection networks.
- Reinfection Management: While SVR12 cures the active infection, it confers no protective immunity. Patients who continue to inject remain susceptible to reinfection (~2% to 6% per person-year in high-risk cohorts). Clinicians must pair DAA therapy with syringe services programs (SSPs), provide sterile preparation equipment, and perform annual post-cure monitoring using HCV RNA PCR (as antibody tests remain permanently positive).
Hepatitis B Virus (HBV): Serology and Accelerated Vaccination Protocols
Hepatitis B is a partially double-stranded DNA virus transmitted via parenteral and sexual routes. In PWID, chronic HBV significantly accelerates progression to cirrhosis and hepatocellular carcinoma, particularly in co-infection with HCV or HIV.
Interpreting the Hepatitis B Serologic Panel
+---------------------------------------------------------------------------------------------------------+
| HBV SEROLOGIC INTERPRETATION PANEL |
+-----------------------+---------+----------+----------+-------------------------------------------------+
| Clinical State | HBsAg | Anti-HBs | Anti-HBc | Clinical Interpretation / APRN Action |
+-----------------------+---------+----------+----------+-------------------------------------------------+
| Susceptible | Neg (-) | Neg (-) | Neg (-) | Never infected, no immunity. VACCINATE. |
| Immune (Vaccinated) | Neg (-) | Pos (+) | Neg (-) | Seroprotected via vaccination (anti-HBs >=10). |
| Immune (Natural) | Neg (-) | Pos (+) | Pos (+) | Natural past infection resolved. Immune. |
| Acute Infection | Pos (+) | Neg (-) | Pos (+) | Active acute hepatitis B (IgM anti-HBc positive)|
| Chronic Infection | Pos (+) | Neg (-) | Pos (+) | Chronic hepatitis B (>6 months); IgM negative. |
| Isolated Core Ab | Neg (-) | Neg (-) | Pos (+) | Distant resolved, occult HBV, or false positive.|
+-----------------------+---------+----------+----------+-------------------------------------------------+
Vaccination Strategies in PWID: Accelerated Regimens
The CDC recommends universal HBV vaccination for all adults aged 19 to 59 and all adults $\ge 60$ with risk factors (including all PWID). In active substance use populations, completion rates for traditional 3-dose, 6-month vaccination schedules (months 0, 1, and 6) are dismal (<20% to 30%).
- Novel 2-Dose Adjuvanted Vaccine (Heplisav-B): Recombinant HBsAg coupled to a novel synthetic cytidine-phospho-guanosine oligodeoxynucleotide (CpG 1018) adjuvant. Administered as two doses at 0 and 1 month. Heplisav-B produces higher seroprotection rates (>95%) in significantly less time, overcoming historical non-compliance in PWID.
- Accelerated 3-Dose Schedule: Where 3-dose vaccines (Engerix-B, Recombivax HB) are used, an accelerated schedule at 0, 1, and 2 months (with a booster at 12 months) achieves rapid seroprotection compared to traditional spacing.
Human Immunodeficiency Virus (HIV): Screening, PrEP & Emergency PEP
HIV transmission among PWID occurs via contaminated blood shared in needles, syringes, cookers, and rinse water. Injection drug use accounts for roughly 7% to 10% of new annual HIV diagnoses in the United States.
Universal Screening
All individuals entering substance use treatment or presenting with injection drug use must undergo opt-out screening with a 4th-generation HIV-1/2 Antigen/Antibody combination immunoassay (detecting both HIV p24 antigen and antibodies). Repeat testing should occur at least annually, or every 3 to 6 months if high-risk injection practices continue.
Pre-Exposure Prophylaxis (PrEP) in PWID
PrEP is a biomedical prevention strategy utilizing antiretrovirals to prevent HIV acquisition in uninfected individuals.
+---------------------------------------------------------------------------------------------------------+
| BIOMEDICAL HIV PrEP FORMULATIONS IN PWID |
+-----------------------------+-----------------------+---------------------------------------------------+
| Formulation | Dosing Regimen | Regulatory Status & Clinical Specifics |
+-----------------------------+-----------------------+---------------------------------------------------+
| Tenofovir Disoproxil | 1 tablet PO daily | FDA-APPROVED for PWID. |
| Fumarate / Emtricitabine | (300 mg / 200 mg) | Backed by Bangkok Tenofovir Study (74-84% risk |
| (TDF/FTC - Truvada) | | reduction with adherence). First-line oral standard|
+-----------------------------+-----------------------+---------------------------------------------------+
| Cabotegravir Long-Acting | 600 mg (3 mL) IM | FDA-APPROVED for at-risk adults, including PWID. |
| Injectable (CAB-LA - | gluteal injection | Initiated with 2 monthly injections, then q2mo. |
| Apretude) | every 2 months | Ideal for PWID struggling with daily oral pills. |
+-----------------------------+-----------------------+---------------------------------------------------+
| Tenofovir Alafenamide / | 1 tablet PO daily | NOT FDA-APPROVED for PWID! |
| Emtricitabine | (25 mg / 200 mg) | Label excludes those at risk via receptive |
| (TAF/FTC - Descovy) | | vaginal sex; not studied in injection exposure. |
+-----------------------------+-----------------------+---------------------------------------------------+
Critical Board Examination Distinction: TAF/FTC (Descovy) is NOT FDA-approved for HIV prevention in PWID or individuals at risk from receptive vaginal sex. The CARN-AP must prescribe TDF/FTC (Truvada) or injectable cabotegravir (Apretude) for injection-related HIV prevention.
Post-Exposure Prophylaxis (PEP)
PEP is the emergency administration of antiretrovirals following an isolated, high-risk exposure (e.g., needle stick, shared syringe with an individual known to be HIV-positive, sexual assault).
- Timing Window: PEP must be initiated as soon as possible, and strictly within 72 hours of exposure. Beyond 72 hours, antiretrovirals are ineffective at aborting viral integration.
- Regimen Duration: A 28-day course of a full 3-drug antiretroviral regimen (e.g., TDF/FTC [Truvada] 300/200 mg daily PLUS dolutegravir [Tivicay] 50 mg daily, or raltegravir [Isentress] 400 mg BID; or bictegravir-based single-tablet regimens where approved).
- Follow-up Protocol: Repeat HIV Ag/Ab testing at baseline, 4-6 weeks post-exposure, and 3 months post-exposure.
Invasive Bacterial and Fungal Infections in PWID
Invasive bacterial and fungal infections represent the leading cause of emergency hospitalization and intensive care admissions among PWID. Repeated venipuncture without skin disinfection introduces cutaneous flora into subcutaneous tissue and venous blood.
Infective Endocarditis (IE)
- Anatomical Distribution: Right-sided endocarditis involving the tricuspid valve is the hallmark of injection-related IE (occurring in 70% to 80% of PWID with IE). The tricuspid valve is vulnerable due to direct trauma from injected particulate adulterants (talc, microcrystalline cellulose) that abrade the endocardium, creating a nidus for microbial adherence.
- Microbiology:
- Staphylococcus aureus: Causative organism in >60% to 70% of cases, with methicillin-resistant S. aureus (MRSA) predominating in many urban centers.
- Streptococcus species & Enterococcus faecalis: Frequent secondary causes.
- Pseudomonas aeruginosa: Historically associated with pentazocine/tripelennamine ("T's and Blues") and waterborne injection practices.
- Fungi (Candida albicans, Candida parapsilosis): Highly morbid fungal endocarditis, often associated with lemon juice or unsterile acidic diluents used to dissolve brown heroin.
- Clinical Presentation & Septic Pulmonary Emboli: Classic peripheral immunological stigmata (Osler nodes, Janeway lesions, Roth spots) are uncommon in right-sided IE. Instead, patients present with high fever, night sweats, leukocytosis, and a dynamic systolic murmur of tricuspid regurgitation. Tricuspid vegetations fragment and embolize into the pulmonary arterial tree, producing septic pulmonary emboli. Patients present with pleuritic chest pain, hemoptysis, cough, dyspnea, and bilateral peripheral nodular or cavitary infiltrates on chest CT.
TRICUSPID VALVE INFECTIVE ENDOCARDITIS CASCADE
Unsterile Inoculation + Particulate Endothelial Abrasion
-> S. aureus / Candida Adherence to Tricuspid Valve Leaflet
-> Mobile Tricuspid Vegetation Formation (>1 cm)
-> Right-to-Left Pulmonary Embolization (Septic Pulmonary Emboli)
-> Cavitary Lung Infarctions, Pleural Effusions, Persistent Bacteremia
In-Hospital Addiction Medicine Consultation: Preventing AMA Discharges
A major clinical crisis in hospital medicine is the premature discharge—specifically discharge Against Medical Advice (AMA)—of PWID admitted with severe infections like endocarditis. Untreated opioid withdrawal is the single greatest driver of AMA discharge (occurring in up to 30% to 50% of hospitalized PWID without addiction care).
Core CARN-AP Hospital Priority: Abruptly withholding opioids or under-treating withdrawal in a patient with life-threatening bacteremia forces the patient into excruciating withdrawal, compelling them to leave the hospital to self-medicate. The CARN-AP must immediately initiate therapeutic MOUD (methadone or buprenorphine), provide aggressive multimodal pain control, and institute non-judgmental nursing protocols. Addiction medicine consultation reduces AMA rates to single digits, ensuring patients complete the mandatory 4 to 6 weeks of parenteral antimicrobial therapy.
Spinal Epidural Abscess (SEA) and Musculoskeletal Infections
- Spinal Epidural Abscess (SEA): Hematogenous seeding of the epidural space, predominantly by S. aureus. Presents with the classic diagnostic triad: (1) localized severe spine pain, (2) fever, and (3) progressive neurological deficits (radicular shooting pain, motor weakness, sensory loss, bladder/bowel incontinence). SEA is a surgical emergency requiring emergent whole-spine MRI with IV contrast and urgent neurosurgical decompression/drainage to prevent irreversible paraplegia.
- Septic Arthritis and Osteomyelitis: PWID frequently present with infections of fibrocartilaginous axial joints: the sternoclavicular joint, sacroiliac joint, and pubic symphysis.
- Skin and Soft-Tissue Emergencies: Subcutaneous injection ("skin popping") carries high risk of extensive subcutaneous abscesses, cellulitis, and life-threatening necrotizing fasciitis (Type I polymicrobial or Type II Streptococcus pyogenes), demanding immediate operative surgical debridement.
A 29-year-old person who actively injects illicit fentanyl presents to an outpatient harm reduction clinic. Laboratory testing reveals: HCV antibody positive, HCV RNA viral load 1,850,000 IU/mL, genotype 1a, baseline liver enzymes AST 48 U/L, ALT 56 U/L, and FIB-4 score 0.82 (no evidence of cirrhosis). The patient acknowledges injecting daily and sharing rinse water occasionally. According to AASLD/IDSA and ASAM guidelines, what is the most appropriate clinical action?
A 33-year-old patient who injects heroin presents to an ambulatory clinic requesting medication to prevent HIV acquisition. The patient does not use condoms during intercourse with multiple partners and frequently shares syringes when supplies are low. The patient's rapid 4th-generation HIV Ag/Ab test is negative, and serum creatinine is 0.9 mg/dL (eGFR >90 mL/min). Which of the following represents an FDA-approved Pre-Exposure Prophylaxis (PrEP) option for this patient's transmission risk profile?
A 27-year-old patient who injects methamphetamine and illicit fentanyl is admitted to the medical floor with high fever (39.2°C), chills, pleuritic chest pain, and cough productive of blood-tinged sputum. Chest CT reveals multiple bilateral peripheral nodular and cavitary lesions consistent with septic pulmonary emboli. Blood cultures grow methicillin-resistant Staphylococcus aureus (MRSA) in 4 of 4 bottles. Transthoracic echocardiogram demonstrates a 1.4 cm mobile vegetation on the tricuspid valve with moderate tricuspid regurgitation. On hospital day 2, the patient exhibits severe restlessness, diaphoresis, pupil dilation, nausea, and abdominal cramping (COWS score 18) and states, 'I am leaving right now because I can't take this sick feeling anymore.' What is the CARN-AP's urgent priority intervention?
A 38-year-old person with a 10-year history of intravenous opioid injection presents to the emergency department with severe, worsening mid-thoracic back pain over the past 5 days that now radiates circumferentially around the chest wall. The patient was febrile to 38.5°C at triage. Over the past 6 hours, the patient has developed progressive bilateral lower extremity weakness and difficulty initiating urination. What life-threatening condition must the CARN-AP immediately suspect, and what is the definitive emergency diagnostic step?